Clinically Node Negative, Pathologically Node Positive Rectal Cancer Patients Who Did Not Receive Neoadjuvant Therapy

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2016 Nov 1

PMID 27796635

Citations 2

Authors

Nouf Akeel

Nan Lan

Luca Stocchi

Meagan M Costedio

David W Dietz

Emre Gorgun

Matthew F Kalady

Georgios Karagkounis

Hermann Kessler

Feza H Remzi

Affiliations

Soon will be listed here.

Abstract

Purpose: Neoadjuvant chemoradiotherapy is the preferred standard of care for clinical stages II-III rectal cancer. It is uncertain whether clinically node negative (cN-) tumors found to be pathologically stage III could be optimally treated with surgery alone and avoid adjuvant treatments. The aim of our study was to define the outcomes of such patients.

Methods: Patients undergoing radical surgery using total mesorectal excision (TME) techniques for rectal cancer (≤12 cm from the anal verge) with curative intent during 2000-2012 and found to have stage III disease on final pathology were identified from a prospectively maintained database. Patients were staged with abdominopelvic CT, transrectal endoscopic ultrasound, and/or pelvic MRI. Exclusion criteria were cN+ without neoadjuvant chemoradiotherapy, hereditary colorectal syndromes, inflammatory bowel diseases, lack of preoperative nodal staging, intraoperative radiotherapy, and follow-up <3 years. We compared cN-/pN+ patients according to the postoperative treatment received (group 1 if no further treatment, group 2 if any postoperative treatments), using ypN+ patients (neoadjuvant chemoradiotherapy + surgery) as controls (group 3). Oncological outcomes evaluated included overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), local recurrence (LR), and distant recurrence (DR).

Results: Out of 218 patients included in the study, 77 cN- patients underwent initial surgery with a pN+ surgical specimen. Eighteen of these patients received no postoperative treatment due to associated comorbidity, patient preference, or postoperative complications while the remaining 59 (group 2) patients received chemoradiotherapy (n = 21) or chemotherapy alone (n = 38), respectively, and group 3 included 141 patients. Distal, radial resection margins and TME grading when available were comparable among groups. cN-/pN+ patients treated with surgery alone were associated with significantly poorer cancer outcomes compared with cN-/pN+ patients who received any form of adjuvant therapy and to ypN+ patients.

Conclusion: TME surgery is not sufficient to optimize outcomes among rectal cancer patients believed to be node negative and found to be stage III based on specimen pathology.

Citing Articles

Is Radical Surgery Alone Enough in T1-3N1a Colon Cancer?.

Xu G, Jin Y, Fang C, Yu J, Zhang Z, Sun C Front Oncol. 2020; 10:1679.

PMID: 33194570 PMC: 7649791. DOI: 10.3389/fonc.2020.01679.

Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers.

Lavryk O, Manilich E, Valente M, Miriam A, Gorgun E, Kalady M Int J Colorectal Dis. 2019; 35(1):77-84.

PMID: 31776698 DOI: 10.1007/s00384-019-03452-6.

References

Fujita S, Akasu T, Mizusawa J, Saito N, Kinugasa Y, Kanemitsu Y . Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 2012; 13(6):616-21. DOI: 10.1016/S1470-2045(12)70158-4. View

Lavery I, Lopez-Kostner F, Fazio V, Milsom J, Church J . Chances of cure are not compromised with sphincter-saving procedures for cancer of the lower third of the rectum. Surgery. 1997; 122(4):779-84; discussion 784-5. DOI: 10.1016/s0039-6060(97)90087-8. View

Wolmark N, Wieand H, Hyams D, Colangelo L, Dimitrov N, Romond E . Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000; 92(5):388-96. DOI: 10.1093/jnci/92.5.388. View

Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham D . Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988; 80(1):21-9. DOI: 10.1093/jnci/80.1.21. View

Kreis M, Ruppert R, Ptok H, Strassburg J, Brosi P, Lewin A . Use of Preoperative Magnetic Resonance Imaging to Select Patients with Rectal Cancer for Neoadjuvant Chemoradiation--Interim Analysis of the German OCUM Trial (NCT01325649). J Gastrointest Surg. 2015; 20(1):25-32. DOI: 10.1007/s11605-015-3011-0. View

Tepper J, Oconnell M, Petroni G, Hollis D, Cooke E, Benson 3rd A . Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol. 1997; 15(5):2030-9. DOI: 10.1200/JCO.1997.15.5.2030. View

Heald R, Husband E, Ryall R . The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?. Br J Surg. 1982; 69(10):613-6. DOI: 10.1002/bjs.1800691019. View

Wibe A, Rendedal P, Svensson E, Norstein J, Eide T, Myrvold H . Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg. 2002; 89(3):327-34. DOI: 10.1046/j.0007-1323.2001.02024.x. View

Tepper J, Oconnell M, Niedzwiecki D, Hollis D, Compton C, Benson 3rd A . Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001; 19(1):157-63. DOI: 10.1200/JCO.2001.19.1.157. View

10.

Lavery I, Lopez-Kostner F, Pelley R, Fine R . Treatment of colon and rectal cancer. Surg Clin North Am. 2000; 80(2):535-69, ix. DOI: 10.1016/s0039-6109(05)70200-0. View

11.

Kariv Y, Kariv R, Hammel J, Lavery I . Postoperative radiotherapy for stage IIIA rectal cancer: is it justified?. Dis Colon Rectum. 2008; 51(10):1459-66. DOI: 10.1007/s10350-008-9346-9. View

12.

Bonadeo F, Vaccaro C, Benati M, Quintana G, Garione X, Telenta M . Rectal cancer: local recurrence after surgery without radiotherapy. Dis Colon Rectum. 2001; 44(3):374-9. DOI: 10.1007/BF02234736. View

13.

Krook J, MOERTEL C, Gunderson L, Wieand H, Collins R, Beart R . Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991; 324(11):709-15. DOI: 10.1056/NEJM199103143241101. View

14.

Taylor F, Quirke P, Heald R, Moran B, Blomqvist L, Swift I . Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011; 253(4):711-9. DOI: 10.1097/SLA.0b013e31820b8d52. View

15.

Lopez-Kostner F, Lavery I, Hool G, Rybicki L, Fazio V . Total mesorectal excision is not necessary for cancers of the upper rectum. Surgery. 1998; 124(4):612-7; discussion 617-8. DOI: 10.1067/msy.1998.91361. View

16.

Gunderson L, Callister M, Marschke R, Young-Fadok T, Heppell J, Efron J . Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. Gastrointest Cancer Res. 2009; 2(1):25-33. PMC: 2630810. View

17.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

18.

Mathis K, Larson D, Dozois E, Cima R, Huebner M, Haddock M . Outcomes following surgery without radiotherapy for rectal cancer. Br J Surg. 2011; 99(1):137-43. DOI: 10.1002/bjs.7739. View

19.

Park J, Jang Y, Choi G, Park S, Kim H, Kang H . Accuracy of preoperative MRI in predicting pathology stage in rectal cancers: node-for-node matched histopathology validation of MRI features. Dis Colon Rectum. 2013; 57(1):32-8. DOI: 10.1097/DCR.0000000000000004. View

20.

Oconnell M, Martenson J, Wieand H, Krook J, Macdonald J, Haller D . Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994; 331(8):502-7. DOI: 10.1056/NEJM199408253310803. View